CN106420827A - Application of Larva ChrysomyiamegacephalaFab. product in preparing dugs, health care products or foods for treating colon cancer - Google Patents
Application of Larva ChrysomyiamegacephalaFab. product in preparing dugs, health care products or foods for treating colon cancer Download PDFInfo
- Publication number
- CN106420827A CN106420827A CN201610808675.8A CN201610808675A CN106420827A CN 106420827 A CN106420827 A CN 106420827A CN 201610808675 A CN201610808675 A CN 201610808675A CN 106420827 A CN106420827 A CN 106420827A
- Authority
- CN
- China
- Prior art keywords
- maggot
- larva
- chrysomyiamegacephalafab
- product
- colon cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 17
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 17
- 230000036541 health Effects 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title claims abstract description 8
- 210000000481 breast Anatomy 0.000 title abstract 2
- 239000000843 powder Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 229920001661 Chitosan Polymers 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 abstract 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 abstract 1
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000202815 Chrysomya megacephala Species 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000257161 Calliphoridae Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001830 phrenic effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000010981 turquoise Substances 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001566735 Archon Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000134068 Mesostigma Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000270934 Rana catesbeiana Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of oncotherapy, in particular to application of a Larva ChrysomyiamegacephalaFab. product in preparing dugs, health care products or foods for treating colon cancer. The Larva ChrysomyiamegacephalaFab. product is a natural product, and the active ingredients of the Larva ChrysomyiamegacephalaFab. product are whole worms of Larva ChrysomyiamegacephalaFab.. According to a modern medical research, it is proved that Larva ChrysomyiamegacephalaFab. contains proteins, fat, chitosan, antimicrobial peptides and 18 kinds of amino acids. The Larva ChrysomyiamegacephalaFab. dry powder contains all active ingredients of the whole worms of Larva ChrysomyiamegacephalaFab., and Larva Chrysomyiae extractives mainly contain fatty acid and/or proteins, peptides, amino acids and the like. According to the study, it is found that the Larva ChrysomyiamegacephalaFab. product can effectively suppress growth of the colon cancer, and has no drug resistance and toxic and side effects of clinically common chemotherapeutic drugs.
Description
Technical field
The present invention relates to a kind of therapeutic field of tumor, more particularly, to maggot product are used for the medicine of preparation treatment colon cancer
Application in product, health products or food.
Background technology
Maggot is Calliphoridae (Calliphoridae) insect chrysomyia megacephala (ChrysomyiamegacephalaFab.)
Or other nearly edge insects larva body is dried, just on the books, for treating infantile malnutrition, pustule sore in medical book in ancient times.
Record maggot at present and there is following pharmacological action：1. antiasthmatic effect, the total amino acid contained by maggot is to relieving asthma
Active ingredient；2. the effect that pair intestines smooth, maggot ethanol extract and maggot total amino acid CE are to histamine institute
The ileum smooth muscle spasm of cause isolated rabbit and cavy all has significantly strives convulsion effect；3. toxicity, the toxicity very little of maggot.
Chinese invention patent application (application number CN200510060277.4 applying date 2005.08.04) one kind has anti-swollen
The cultural method of knurl biologically active fly maggot.Through The National Center for Drug Screening, in the past few years repeated detection has to liver the fly maggot of cultivation
Cancer, breast cancer, oophoroma, cervical carcinoma, lung cancer, cancer of the stomach, etc. growth of tumour cell have very strong inhibiting rate, its anti-tumor biological live
Property is all 75%～97%.
Chinese invention patent application (application number CN200710067951.0 applying date 2007.04.10) discloses a class and resists
Neoplastic compound, this component extracting and developing from the fly maggot that allogenic material induces obtains, and has suppression people's promyelocytic leukemia
HL-60 and the effect of human pulmonary epithelial cells propagation growth.
Chinese invention patent application (application number CN201310223817.0 applying date 2013.06.06) discloses a kind of five
Paddy worm antineoplastic new usage, is showed by the effect that maggot suppresses mouse tumor weight, maggot can suppress tumour cell
Growth, to tumour cell, there is lethal effect, can apply in preparing antineoplastic or health products, specifically disclose little
The growth inhibition of mouse euphorbia egg decoctum.
Colon cancer is the common malignant tumor of digestive tract betiding colon site, is apt to occur in rectum and has a common boundary with sigmoid colon
Place, with 40～50 years old age group incidence of disease highest, the ratio of men and women was 2～3：1.The incidence of disease accounts for the 3rd of gastroenteric tumor.Colon
Cancer is mainly gland cancer, mucinous adenocarcinoma, undifferentiated carcinoma.General form is in polypoid, ulcer type etc..Colon cancer can be gone in ring along intestinal wall and be sent out
Exhibition, indulges footpath along intestinal tube and spreads up and down or to the infiltration of intestinal wall deep layer, in addition to through lymphatic vessel, blood flow transfer and local Invasion, also can be to
Plant or along suture, cut sides diffusion transfer in abdominal cavity.Patients with chronic colitis, polyp of colon patient, male overweight person etc. are
Susceptible population.
Content of the invention
First purpose of the present invention is the application in the medicine providing maggot product to be used for preparation treatment colon cancer.
Second object of the present invention is the application in the health products providing maggot product to be used for preparation suppression colon cancer.
Second object of the present invention is the application in the food providing maggot product to be used for preparation suppression colon cancer.
Preferably, above-mentioned maggot product be maggot dry powder and or maggot extract and maggot dry powder
With or maggot extract preparation preparation.
As further preferably, described preparation is capsule, tablet, pill, powder, compound granule, health liquor, albumen
Powder, oral liquid or freeze-dried powder.
Preferably, above-mentioned maggot extract includes the water extract of the full worm of maggot or maggot dry powder and organic
One or more of solvent extractable matter.
As further preferably, the organic solvent in described extractive with organic solvent is included in ethanol, petroleum ether or hexane
One or more.
The maggot product of the present invention is a kind of natural product, and maggot product active ingredient is the full worm of maggot, existing
Prove for medical research：Contain protein, fat, chitosan in maggot, contain antibacterial peptide and 18 kinds of amino acid.The present invention's
All active ingredients of the full worm of maggot are included, maggot extract is mainly with aliphatic acid and/or egg in maggot dry powder
White matter, polypeptide, amino acid etc..It has been investigated that, maggot product effectively can suppress Growth of Human Colon Cancer, and maggot product is not
There is the resistance of chemotherapeutic clinically commonly used and its toxic and side effect.
Specific embodiment
Embodiment 1
1st, Hylemyia Platura Meigen selects
Zoology is identified：Calliphoridae Calliphoridae insect chrysomyia megacephala Chrysomyia megacephala
(Fab.).8～11 millimeters of adult flies body length, turquoise, head width, top black；Compound eye is big, peony, frontalia maroon, face
Orange-yellow with cheek, feeler and palpuli brown.Chest, belly turquoise, with purple gloss.After 1st uromere and the 2nd, 3 uromere
Edge black.The forehead of female fly and middle bar slightly protrude laterally in center.The facet of big shape is arranged at male fly compound eye top 2/3,
Lower section 1/3 is then the facet of little shape, the two interface is clear.Prothoracic spiracles black, mesostigma is light brown；There is valve.Proxacalypteron
Band brown, above has little Mao.Yellow-white during larval maturation, front end is tapering, and rear end is truncated.Body segment 14, head 1 saves, and chest 3 saves, abdomen
Portion 10 saves, but generally only sees 8 sections.The ring that body surface is formed by clavula.Valve is slightly higher than surface afterwards, more flat in top, spiracular annulus is not
Completely；The transverse diameter of valve after valve spacing is not more than afterwards；The vertical shape of 1st ostium；Front valve has 10 13 finger-like and dashes forward.
2nd, Hylemyia Platura Meigen collection
(1) making of Hylemyia Platura Meigen case：Wooden, glass, ceramic making can be selected, circular or rectangle, top stays one
The mouth of 25 centimetres of individual diameter, and make the netted lid that a use is breathed freely, in case Hylemyia Platura Meigen escapes.
(2) Hylemyia Platura Meigen feed configuration：Milk powder+brown sugar, 1:1 mixing, the water plus 15% is in harmonious proportion, is positioned in Hylemyia Platura Meigen case.
(3) open the netted lid of Hylemyia Platura Meigen case, be placed in 28--38 degree Celsius, humidity is less than in 65% environment.
Allow the chrysomyia megacephala in the external world to enter in cartonning to look for food, undesirable fly kind is carried out with sorting and abandons, and cover net
Shape lid is looked for food, lays eggs so as to be stranded in Hylemyia Platura Meigen case.
3rd, cultivation hardware and breeding feed
(1) fly house is built：By cultivation scale, masonry can be selected, glass, plastics, steel frame construction material, 2 meters from the ground
1.5--2 rice setting vent window in interval on the body of wall of left and right, for preventing other flies or insect from entering, be preferably provided with screen window with extraneous
Isolation, above box for breeding, a metric system becomes mobilizable ventilation shaft, is easy to gas sampling, prevents emission of bad smell pollution environment,
Waste gas unification is discharged after being processed by ozone deodorizer.For preventing fly kind from entering gas sampling pipeline, preferably set in each air inlet
Put screen window cut-off.
(2) box for breeding makes：Wooden, ceramic, cement material can be selected, make rectangular box, bottom arranges sealing
Sealing device, stays the circular hole of 30--40 centimetre of a diameter above casing, you can.It is provided with sewage collecting below each box for breeding to lead to
Road, unified entrance after cesspool is processed is discharged.
(3) it is incubated：For meeting the standardisation requirements of cultured product, can set up heat, cooling installation.In sweltering heat, season can
In fly house top surface, anti-sunshading facility is set.
(4) breeding feed：Haslet, fresh-water fishes, bullfrog, milk powder, honey.
4th, breeding technique step
(1) fly kind：The fly kind of collection is transplanted to and is carried the previous day and be placed with the Hylemyia Platura Meigen case of fresh-water fishes, cultivates 2 days, treats it in case
Interior spawning.
(2) collect fly blow：Treat that Hylemyia Platura Meigen lays eggs in fly kind case, you can fly blow is collected, transfers to the fly house added with feed
Carry out in box for breeding hatching, cultivate, the ratio of feed and fly blow is every 5 grams of fly blows, adds 15 kilograms of feed.
(3) hatching cultivation：After fly blow hatching, you can obtain required feed in box for breeding, generally require 72 hours, worm
Body grows to length 1--1.2 centimetre, during diameter 2.5--3 millimeter.
(4) active catalytic：In box for breeding add with 200 milliliters of prewired 5% sucrose (w/w) aqueous solution and 1% surpass
500 milliliters of superoxide dismutase (LA-SOD) (activities of the enzyme systems is more than 3,000,000 units/gram), took out live body maggot after 2 hours,
Repeatedly rinsed well with clear water, at once put into quick-frozen in less than 38 degrees Celsius of refrigerator-freezer.
(5) cleaning-drying：Low-temperature quick-freezing two days later, takes out, and melts, more carefully cleans, drain away the water in clear water, uses
Vacuum dehydrating at lower temperature equipment is dried to moisture and is less than 10%.
Test example 1
First, experiment purpose
Evaluate the extracorporeal anti-tumor function to human colon cancer cell HT-29 for the maggot full worm powder.
2nd, major experimental instrument and material
1. key instrument
Wavelengthtunable declines orifice plate ELIASA.
2. main agents
Maggot entirety thing, our company cultivates；DMEM high sugar fully liquid culture medium, purchased from Nanjing Kai Ji biotech firm；
MTT. three, experimental technique and step
Experimental technique:
MTT principle:MTT, a kind of dyestuff of yellow color.In living cells mitochondria, succinate dehydrogenase being capable of metabolism reduction
MTT, simultaneously in the presence of cromoci, generates blue (or bluish violet) water-fast first (Formazan), first
How much can be measured at 490nm with ELIASA.Under normal conditions, first growing amount is directly proportional to viable count, because
This can deduce the number of living cells according to optical density OD value.Due to not containing succinate dehydrogenase in dead cell, therefore add MTT
Do not have reaction.
Experimental procedure：
Maggot sample treatment.With 1:5 ratio, 10 degrees Celsius of distilled water soaks 24 hours, filter and remove residue, every milliliter of phase
When in 0.2 gram of material sample, standby.
1:Collect logarithmic phase cell, adjust concentration of cell suspension, every hole adds 150ul, bed board makes cell to be measured adjust density
1*105/ hole, (edge hole is filled with aseptic PBS).
2:5%CO2, 37 DEG C of incubations, it is paved with bottom hole (96 hole flat underside) to cell monolayer, add the medicine of 3 concentration gradients
(stage extraction compound is 0.063mg/ml, 0.25mg/ml, 0.5mg/ml to thing；Overall compound is 0.25mg/ml, 0.5mg/
Ml, 1mg/ml), every hole 50ul, if 3 multiple holes. zero hole (culture medium, MTT, dimethyl sulfoxide (DMSO)) simultaneously, control wells (cell, phase
With the medicine dissolving medium of concentration, nutrient solution, MTT, dimethyl sulfoxide (DMSO))；5%CO2,37 DEG C are incubated 48 hours, inverted microscope
Lower observation.
3:Every hole adds 20ulMTT solution (5mg/ml), continues culture 4h；Terminate culture, carefully suck in the hole nutrient solution
Every hole adds 150ul dimethyl sulfoxide (DMSO), puts vibration 10min on shaking table, so that crystal is fully dissolved.Enzyme-linked immunosorbent assay instrument
The light absorption value in each hole is measured at OD490nm.
4：Calculate the inhibiting rate to cancer cell growth for the test compound by following equation.
Inhibiting rate=(1- control group OD value/administration group OD value) × 100%
4th, experimental result：
Table one：The inhibiting rate to HT-29 cell growth for each tested overall thing
This MTT experiment testing result shows：Overall thing sample acts on all very bright to the Developing restraint of human colon cancer cell
Aobvious.
Test example 2
King * *, sex:Female, the age：31, address：Changxing.
In March, 2010 patient is indefinite because discontinuity full abdomen secret anguish, painful area, and Right Lower Abdomen has lump.Then go to
Hospital is checked, is diagnosed as transverse colon poorly differentiated adenocarcinoma.Patient is on April 2nd, 2010 in Tumor Hispital Attached to Fudan Univ
Row operation.
In June, 2010, cancer patients March checks, and finds multiple occupy-place in liver, 2 centimetres of diameter, sees multiple after peritonaeum
Small lymph node shifts.Carried out radiotherapy.
On July 15th, 2011 starts clothes and accepts antitumor maggot oral medication, checks after four months, and hepatic region MET is big
Piece low-density shadow significantly reduces, and maximum gauge narrows down to 0.3 centimetre by 2 centimetres.Rabat no abnormality seen, belly color ultrasound is normal, body
Body is in order.
So far, patient takes nearly 2 years, check index checking report display, and most of Testing index is normal, and recovery situation is good
Good, still adhere to after treatment of taking medicine.
Test example 3
Poplar * *, sex:Female, the age：42, address：Guangde County
Patient Yang Jinfeng, female, 42 years old, in August, 2011 part was diagnosed as differentiation gland cancer in colon, double in Central Hospital of Huzhou
Lung, vertical phrenic lymph nodes transfer, after being treated surgically, in October after three chemotherapeutic treatments of Zhejiang Prov. Tumor Hospital's row, suffer from
Person's self-induction is uncomfortable, and the state of an illness is not effectively controlled and recurrence trend, and patient abandons continuing to accept chemotherapeutic treatment then
And handle discharge.
Medical record brief introduction：
After patient discharge, started oral antitumor maggot treatment in 2012 2 months, period, patient did not accepted other drugs
And means treatment, the state of an illness before medication：Two lung marking are slightly many, the visible multiple brief summary nodular high density shadow of two lung fields, obscure boundary, lung
Door and vertical phrenic lymph nodes enlargement, 2.6 centimetres of diameter, splenomegaly, up to 8 rib units.Archon is than row 1.05.
Medication 9 months, on November 13rd, 2012 checks, and image report shows, high density shade periphery is still clear, and lymph node contracts
Little to 0.6 centimetre, spleen is slightly larger.Every tumor markers checks normal, 4.8 kilograms of body weight increase.Patient body situation is recovered
Well, no significant discomfort, pain, still in after treatment.Diet can.General housework matters can be completed.
Claims (7)
1. maggot product is used for the application in the medicine of preparation treatment colon cancer.
2. maggot product is used for the application in the health products of preparation suppression colon cancer.
3. maggot product is used for the application in the food of preparation suppression colon cancer.
4. the application according to claim 1 ~ 3 any one claim is it is characterised in that maggot product is maggot
Dry powder and or maggot extract and maggot dry powder and or the preparation of maggot extract preparation.
5. application according to claim 4 is it is characterised in that preparation is capsule, tablet, pill, powder, compound granular
Agent, health liquor, albumen powder, oral liquid or freeze-dried powder.
6. application according to claim 4 is it is characterised in that maggot extract includes the full worm of maggot or maggot does
One or more of the water extract of powder and extractive with organic solvent.
7. application according to claim 6 is it is characterised in that the organic solvent in extractive with organic solvent includes ethanol, stone
One or more of oily ether or hexane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/100684 WO2018045959A1 (en) | 2016-09-08 | 2017-09-06 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610108953 | 2016-02-26 | ||
| CN2016101089539 | 2016-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420827A true CN106420827A (en) | 2017-02-22 |
Family
ID=58165153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610808675.8A Pending CN106420827A (en) | 2016-02-26 | 2016-09-08 | Application of Larva ChrysomyiamegacephalaFab. product in preparing dugs, health care products or foods for treating colon cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420827A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (en) * | 2016-09-08 | 2018-03-15 | 黄玉水 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
| CN109091503A (en) * | 2018-10-18 | 2018-12-28 | 江苏毅成生物科技有限公司 | Preparation method and applications of the maggot in preparation treatment enteritis drug |
| CN109394792A (en) * | 2018-12-20 | 2019-03-01 | 大连麦琪克生物技术有限公司 | A kind of preparation method of Calliphoridae insect larvae extract |
| CN110279720A (en) * | 2019-07-31 | 2019-09-27 | 浙江佰科堂生物科技股份有限公司 | A kind of maggot processed product and its application in adjusting intestinal flora |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991608A (en) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | Fly maggot extractive as well as preparation method and application thereof |
-
2016
- 2016-09-08 CN CN201610808675.8A patent/CN106420827A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991608A (en) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | Fly maggot extractive as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 云贵: "水仙子昆虫蛋白研究概况", 《上海医药》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (en) * | 2016-09-08 | 2018-03-15 | 黄玉水 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
| CN109091503A (en) * | 2018-10-18 | 2018-12-28 | 江苏毅成生物科技有限公司 | Preparation method and applications of the maggot in preparation treatment enteritis drug |
| CN109394792A (en) * | 2018-12-20 | 2019-03-01 | 大连麦琪克生物技术有限公司 | A kind of preparation method of Calliphoridae insect larvae extract |
| CN110279720A (en) * | 2019-07-31 | 2019-09-27 | 浙江佰科堂生物科技股份有限公司 | A kind of maggot processed product and its application in adjusting intestinal flora |
| CN110279720B (en) * | 2019-07-31 | 2020-10-23 | 浙江佰科堂生物科技股份有限公司 | Processed maggot product and application thereof in regulating intestinal flora |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106420827A (en) | Application of Larva ChrysomyiamegacephalaFab. product in preparing dugs, health care products or foods for treating colon cancer | |
| CN106420826A (en) | Application of oriental latrine fly larvina product in preparing drugs, health care products or foods for treating lymphoma | |
| CN107551254A (en) | A kind of Chinese medicine composition with preventing and treating Colon and rectum precancerous lesion and preparation method and application | |
| CN107397208A (en) | Using fish glue as functional food of principal component and application thereof | |
| Ergashov et al. | EMERIOSIS OF RABBITS (LITERATURE ANALYSIS) | |
| CN102212581A (en) | Preparation method and application of cordyceps polysaccharide germanium | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN109718273A (en) | Perilla leaf extract is preventing or is treating the application in Osteoarthritis | |
| CN104922268B (en) | A kind of method that active material is extracted from natural plants | |
| CN106420829A (en) | Application of maggot product to preparation of medicine, health care product or food for treating gliocytoma | |
| CN115192642A (en) | Preparation method and application of composite biological preparation with parasite killing function and containing brevibacillus laterosporus and fermented traditional Chinese medicine | |
| CN106265753A (en) | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food | |
| WO2018045959A1 (en) | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product | |
| CN105769895A (en) | intervention effect of cyanidin-3-O-glucoside on reproductive toxicities of acrylamide and glycidamide | |
| CN108452240B (en) | Anti-tumor traditional Chinese medicine composition and application thereof | |
| CN105661522A (en) | Method for recommending blood sugar stabilization to patient with Type 2 diabetes | |
| Molefe | Anthelmintic, anticancer and phytochemical screening of Cotyledon orbiculata; Hermannia depressa; Nicotiana glauca and potassium permanganate | |
| CN108888754A (en) | A kind of anti-tumor compositions and its application containing ubenimex and trail protein | |
| CN103845524B (en) | It is a kind of to treat the Chinese medicine composition and preparation method and purposes that kidney essence deficiency is demonstrate,proved after tumor radiotherapy, chemotherapy | |
| CN101066410B (en) | Chinese medicine preparation for treating women's chronic pelvic inflammation and its preparation process | |
| CN109662970B (en) | A kind of application of lanostane-type | |
| CN107007826A (en) | Radix Isatidis activated protein and preparation method and application | |
| CA3103922C (en) | A natural product comprising fermented fig to combat viral diseases, bacterial diseases, fungus diseases and cancer diseases | |
| CN105535437A (en) | Traditional Chinese medicine composition for treating malignant tumors of upper gastrointestinal tract and preparing method | |
| CN104784657A (en) | Application of traditional Chinese veterinary medicine compound preparation for preparing medicine for treating chicken colibacillosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| RJ01 | Rejection of invention patent application after publication |